Innovative Approaches to Investigating KRAS Therapeutics with Biochemical and Cell-Based Assays
Kirsten rat sarcoma viral oncogene homologue (KRAS) is the most frequently mutated oncogene, present in approximately 25% of tumors. Despite drug-targeting attempts over the past four decades, KRAS has been labeled a difficult — even “undruggable” — therapeutic target; recent advances such as the FDA approval of Amgen’s sotorasib encourage new progress in the field.
This webinar explores methods to discover and qualify KRAS inhibitors with downstream signaling and binding assays, using no-wash HTRF® and AlphaLISA® technology.
Key Learning Objectives
- How to screen compounds with binding assays to identify positive hits and competitors
- Detection of MAPK activation to evaluate the efficacy and potency of KRAS inhibitors
- Data supporting indirect targeting of KRAS (RAF–MEK approach) and direct targeting with KRAS-SOS1 and KRAS G12 inhibitors
Watch Now: Innovative Approaches to Investigating KRAS Therapeutics with Biochemical and Cell-Based Assays
This webinar is available on demand. Fill in the form to watch the full recording — we'll email you the link too.
- June 15, 2022
- kbiinfo@krishgen.com
- +91 22 49198700
Your details
Request the recording
Fill in your details and we'll email you the recording.
More Webinars
Shortcuts to Discovery and Characterization of Monoclonal Antibodies
Monoclonal antibody (mAb) discovery and characterization often face significant delays due to iterative screening cycles, late-stage functional failures, and downstream analytical bottlenecks. This webinar details five practical shortcuts that accelerate timelines from target validation to preclinical characterization.
View Webinar June 12, 2026Viral Vectors & CRISPR for Building Disease Models
Gene editing and viral vector technologies are transforming the development of advanced disease models for translational research.
View Webinar April 17, 2026Advanced Immunocompetent Primary Human Airway Models for Respiratory Disease Modeling
Advancements in human-relevant in vitro models are transforming how respiratory diseases are studied and how drug safety and efficacy are evaluated.
View Webinar